Cancer is one of the most serious public health problems facing humanity in the world. In the face of rising cancer incidence and high mortality, how to treat cancer correctly has become a topic of great concern. Targeted therapy is a cancer treatment that targets tumors by interfering with the growth, division and spread of cancer cells. Targeted therapies are also referred to as "molecular targeted therapy" or "precision medicine". Targeted therapy focuses on targeting tumor-related specific molecules based on tumor molecular biology. In most of these therapies, tumor markers are used as therapeutic targets. In addition, various factors involved in the abnormal signal transduction, cell cycle, tumor internal environment and tumor blood vessels during the process of tumor occurrence, development, growth and metastasis can be used as tumor therapeutic targets. Currently, oncology drugs include monoclonal antibodies, selective kinase inhibitors, anti-angiogenesis inhibitors, apoptosis inducers, telomerase inhibitors, and cyclin inhibitors, as well as the treatment of various tumor genes and tumor vaccines. Understanding the underlying cellular and molecular mechanisms is essential for the development of novel and efficient targeted cancer therapy.
The detailed pathophysiological mechanisms of cancer progression are complex and far from being completely clear. A number of targeted cancer drugs have been detected and identified by cell or animal models, which are based on novel targets that control the cancer cell fate. This Research Topic aims at collating articles related to the newly developed targets in cancer clonal evolution, heterogeneity, epithelial-mesenchymal transition, migration, invasion, metastasis, neovascularization, apoptosis, microenvironment and treatment resistance, and pre-clinical cancer-targeted drugs. We encourage interested investigators to submit original research, reviews, clinical trials and case reports to promote the research progress of cancer-targeted therapy.
Potential topics include but are not limited to the following:
• Identifying small molecule drugs and monoclonal antibodies for cancer-targeted therapy
• Roles and mechanisms of novel targets in cancer development
• Impact of molecularly targeted agents combined with cytokine or chemotherapy agents on cancer progression
• Application based on bioinformatics in targeted cancer therapy
Cancer is one of the most serious public health problems facing humanity in the world. In the face of rising cancer incidence and high mortality, how to treat cancer correctly has become a topic of great concern. Targeted therapy is a cancer treatment that targets tumors by interfering with the growth, division and spread of cancer cells. Targeted therapies are also referred to as "molecular targeted therapy" or "precision medicine". Targeted therapy focuses on targeting tumor-related specific molecules based on tumor molecular biology. In most of these therapies, tumor markers are used as therapeutic targets. In addition, various factors involved in the abnormal signal transduction, cell cycle, tumor internal environment and tumor blood vessels during the process of tumor occurrence, development, growth and metastasis can be used as tumor therapeutic targets. Currently, oncology drugs include monoclonal antibodies, selective kinase inhibitors, anti-angiogenesis inhibitors, apoptosis inducers, telomerase inhibitors, and cyclin inhibitors, as well as the treatment of various tumor genes and tumor vaccines. Understanding the underlying cellular and molecular mechanisms is essential for the development of novel and efficient targeted cancer therapy.
The detailed pathophysiological mechanisms of cancer progression are complex and far from being completely clear. A number of targeted cancer drugs have been detected and identified by cell or animal models, which are based on novel targets that control the cancer cell fate. This Research Topic aims at collating articles related to the newly developed targets in cancer clonal evolution, heterogeneity, epithelial-mesenchymal transition, migration, invasion, metastasis, neovascularization, apoptosis, microenvironment and treatment resistance, and pre-clinical cancer-targeted drugs. We encourage interested investigators to submit original research, reviews, clinical trials and case reports to promote the research progress of cancer-targeted therapy.
Potential topics include but are not limited to the following:
• Identifying small molecule drugs and monoclonal antibodies for cancer-targeted therapy
• Roles and mechanisms of novel targets in cancer development
• Impact of molecularly targeted agents combined with cytokine or chemotherapy agents on cancer progression
• Application based on bioinformatics in targeted cancer therapy
